{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T17:47:16Z","timestamp":1706723236254},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,1,22]],"date-time":"2013-01-22T00:00:00Z","timestamp":1358812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cyclo\u2010oxygenase (<jats:styled-content style=\"fixed-case\">COX<\/jats:styled-content>)\u20102 inhibitors have been the target of severe criticism, more so following the withdrawal of Rofecoxib. Post\u2010marketing surveillance of Celecoxib in Asian Indians, who are predisposed to premature athero\u2010thrombotic events, has not been studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To study the adverse effects of Celecoxib and compare them with those of other non\u2010steroidal anti\u2010inflammatory drugs (<jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>s) in an Asian Indian cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>This is a retrospective chart review with convenience sampling of patients on <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>s (at least five tablets a week, for at least 3\u00a0months prior to the study), attending the Rheumatology clinic of a tertiary care institution in south India between June 2004 and November 2004. Those with pre\u2010existing heart disease, hypertension, thrombo\u2010embolic disease, peptic ulcer and patients on corticosteroids were excluded. All the recorded adverse events were noted and compared between the Celecoxib and non\u2010selective <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content> users. Univariate analysis using Chi\u2010square test was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 1387 patients included, 915 were on Celecoxib. In the <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content> group, 204 had used multiple <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>s in sequence. Of the Celecoxib users, 164 had switched over to an <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content> during the study period. New onset of hypertension was significantly higher in the Celecoxib users as compared to non\u2010selective <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content> users (3.06% <jats:italic>vs<\/jats:italic>. 1.27%, <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.04). However, those who had switched over to <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>s did not show this trend. <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content> users, on the other hand, had significant gastrointestinal (<jats:styled-content style=\"fixed-case\">GI<\/jats:styled-content>) toxicity (2.54% <jats:italic>vs<\/jats:italic>. 0.327%, <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.001). A significant number of Celecoxib users who switched over to <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>s also developed <jats:styled-content style=\"fixed-case\">GI<\/jats:styled-content> toxicity (6.1% <jats:italic>vs<\/jats:italic>. 1.21%, <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.018) over a shorter time span, as compared to the continuous <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content> users. Multiple <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content> users had higher adverse events (6.37% <jats:italic>vs<\/jats:italic>. 2.23%, <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.023) as compared to single <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content> users.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Celecoxib significantly increased the incidence of new onset hypertension in this cohort of Indian patients with rheumatic diseases. No thromboembolic events were documented.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.12043","type":"journal-article","created":{"date-parts":[[2013,1,22]],"date-time":"2013-01-22T06:26:37Z","timestamp":1358835997000},"page":"24-29","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["How safe is Celecoxib for Asian\u2013Indian patients with rheumatic diseases?"],"prefix":"10.1111","volume":"16","author":[{"given":"Debashish","family":"Danda","sequence":"first","affiliation":[{"name":"Departments of Clinical Immunology and Rheumatology Christian Medical College Vellore Tamil Nadu India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed M.","family":"Iliyas","sequence":"additional","affiliation":[{"name":"Departments of Pharmacology \u2013 Pharmacy Services Christian Medical College Vellore Tamil Nadu India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujith J.","family":"Chandy","sequence":"additional","affiliation":[{"name":"Departments of Pharmacology \u2013 Pharmacy Services Christian Medical College Vellore Tamil Nadu India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheemalapati","family":"Chandra","sequence":"additional","affiliation":[{"name":"Departments of Pharmacology \u2013 Pharmacy Services Christian Medical College Vellore Tamil Nadu India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish J.","family":"Mathew","sequence":"additional","affiliation":[{"name":"Departments of Clinical Immunology and Rheumatology Christian Medical College Vellore Tamil Nadu India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612033453965"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.20.1921"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7365.624"},{"key":"e_1_2_6_5_1","first-page":"229","volume-title":"Non steroidal anti\u2010inflammatory drugs. In: Pharmacology","author":"Rang HP","year":"2000"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.8.840"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050493"},{"key":"e_1_2_6_9_1","first-page":"26","article-title":"Atherothrombotic risk factors and premature coronary heart disease in India: a case control study","volume":"134","author":"Panwar RB","year":"2011","journal-title":"Indian J Med Res"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20853"},{"key":"e_1_2_6_11_1","first-page":"2167","article-title":"Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis","volume":"33","author":"Han C","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.75"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg379"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02198.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.020313"},{"key":"e_1_2_6_16_1","first-page":"395","article-title":"The COX\u20102 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk","volume":"27","author":"Greenberg JD","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_17_1","first-page":"49","article-title":"Clinical pharmacology of selective COX\u20102 inhibitors","volume":"16","author":"Capone ML","year":"2003","journal-title":"Int J Immunopath Pharmacol"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/862153"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001766"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703232"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000014323.99765.16"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.636746"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.126182"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000160358.63804.C9"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12043","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:16:33Z","timestamp":1697426193000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,22]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/1756-185X.12043"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12043","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,22]]},"assertion":[{"value":"2013-01-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}